Image de couverture de livre

Impact of Sampling Window Variability on Pharmacokinetic Parameters Estimated by Non‐Compartmental Analysis: Case Studies of Various Types of Drugs

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Kyosuke Takahashi, Kazuhiko Asari, Kazuhiko Hanada
Format:	Artículo Open Access
Publié:	Wiley 2026
Sujets:	Clinical Pharmacology in Drug Development
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Phase 1 Mass Balance Study of Pizuglanstat: An Investigational Hematopoietic Prostaglandin D Synthase Inhibitor
par: Ryuzo Hanada, et autres
Publié: (2025)

Impact of Sotorasib, a KRAS G12C Inhibitor, on the Pharmacokinetics and Therapeutic Window of Digoxin, a P‐Glycoprotein Substrate
par: Panli Cardona, et autres
Publié: (2025)

Lack of Pharmacokinetic Drug–Drug Interactions Between Bepirovirsen and Nucleos(t)ide Analogs
par: Kelong Han, et autres
Publié: (2025)

A Phase 1 Study to Evaluate the Pharmacokinetic Drug‐Drug Interaction Between Islatravir and Methadone in Participants on Stable Methadone Therapy
par: Randolph P. Matthews, et autres
Publié: (2024)

Physiologically Based Pharmacokinetic Absorption Model for Pexidartinib to Evaluate the Impact of Meal Contents and Intake Timing on Drug Exposure
par: Shintaro Nakayama, et autres
Publié: (2024)

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants
par: Matthias Hoch, et autres
Publié: (2025)

Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters to Evaluate the Impact of CYP2C19 and CYP2C9 Genetic Polymorphisms on Abrocitinib Exposure
par: Luke Fostvedt, et autres
Publié: (2024)

Pharmacokinetics and Safety of Atogepant Co‐administered with Quinidine Gluconate in Healthy Participants: A Phase 1, Open‐Label, Drug‐Drug Interaction Study
par: Ramesh Boinpally, et autres
Publié: (2024)

Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug‐Drug Interaction of Avacopan in 2 Open‐Label Studies in Healthy Participants
par: Shichang Miao, et autres
Publié: (2024)

A Phase 1 Dose‐Escalation, Food Effect, and Drug–Drug Interaction Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MALT1 Inhibitor, SGR‐1505, in Healthy Volunteers
par: Vipul K. Gupta, et autres
Publié: (2026)

Impact of Acid‐Reducing Agents on Sotorasib Pharmacokinetics and Potential Mitigation of the Impact by Coadministration With an Acidic Beverage
par: Panli Cardona, et autres
Publié: (2024)

Comparative Pharmacokinetics and Safety Assessment of 1st‐ and 2nd‐Generation Zinpentraxin Alfa Drug Products in Healthy Volunteers: A Randomized Crossover Study
par: Tu H. Mai, et autres
Publié: (2024)

Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P–Glycoprotein Inhibition
par: Hongxia Jia, et autres
Publié: (2025)

Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Recombinant Neorudin, a New Anticoagulant Drug in Patients With Acute Coronary Syndrome
par: Yu‐bin Liu, et autres
Publié: (2024)

Physiologically Based Pharmacokinetic Modeling to Evaluate Drug‐Drug Interactions of Tacrolimus With Ritonavir, a CYP3A Irreversible Inhibitor: Applications for Dosing Optimization in Transplant Patients
par: Yanjun Jiang, et autres
Publié: (2025)

A Drug‐Drug Interaction Study to Evaluate the Impact of Rimegepant on OCT2‐ and MATE1‐Mediated Transport of Metformin in Healthy Participants
par: Rajinder Bhardwaj, et autres
Publié: (2024)

Safety, Tolerability, and Pharmacokinetic Profile of the Low‐Impact Ampakine CX1739 in Young Healthy Volunteers
par: Daniel P. Radin, et autres
Publié: (2024)

Impact of a High‐Fat Meal on the Pharmacokinetics of Sotorasib, a KRAS G12C Inhibitor
par: Panli Cardona, et autres
Publié: (2024)

A Population Pharmacokinetic Assessment of the Effect of Food on Selumetinib in Patients with Neurofibromatosis Type 1‐Related Plexiform Neurofibromas and Healthy Volunteers
par: Peiying Zuo, et autres
Publié: (2024)

A Drug–Drug Interaction Study of Mobocertinib and Midazolam, a Cytochrome P450 3A Substrate, in Patients With Advanced Non–Small Cell Lung Cancer
par: Michael J. Hanley, et autres
Publié: (2025)

Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults
par: Caroline A. Lee, et autres
Publié: (2024)

Pharmacokinetics of Aztreonam–Avibactam After Single‐ and Multiple‐Dose Administration: A Phase 1, Open‐Label Study in Healthy Chinese Participants and Ethnic Comparison with Non‐Chinese Participants
par: Jingjing Wang, et autres
Publié: (2026)

Effect of Renal Impairment on the Pharmacokinetics and Safety of Doxecitine and Doxribtimine: A Single‐Dose Phase 1 Study
par: Aravind Mittur, et autres
Publié: (2026)

Randomized Phase 1 Studies Evaluating the Safety, Tolerability, Pharmacokinetics, and Target Occupancy of Zampilimab in Healthy Participants
par: Jo Collier, et autres
Publié: (2026)

Pharmacokinetics, Safety, and Skin Irritation and Sensitization Potential of Clascoterone Cream in Early‐Phase Clinical Study Participants
par: Andrea Francesco Daniele Di Stefano, et autres
Publié: (2025)

Effect of Carbamazepine on the Pharmacokinetics of Erdafitinib in Healthy Participants
par: Pharavee Jaiprasart, et autres
Publié: (2024)

Safety and Pharmacokinetics of Single‐Dose Mirikizumab in Chinese Healthy Participants: Results From a Phase 1 Study
par: Junyu Xu, et autres
Publié: (2024)

Pharmacokinetics and Bioequivalence of Vardenafil Hydrochloride in Healthy Chinese Volunteers
par: Sheng He, et autres
Publié: (2024)

Population Pharmacokinetics of Naloxegol in Pediatric Subjects Receiving Opioids
par: Matthew W. Hruska, et autres
Publié: (2024)

A Comparative Analysis of the Pharmacodynamic and Pharmacokinetic Properties of 2 Controlled‐Release Formulations Versus a Marketed Orlistat Product
par: Stefan Grudén, et autres
Publié: (2025)

A Phase 1, Open‐Label, Single‐Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor
par: Wei Zhu, et autres
Publié: (2026)

Pharmacokinetics and Safety Evaluation of a New Generic Sitafloxacin: A Phase I Bioequivalence Study in Healthy Chinese Participants
par: Yongfang Lei, et autres
Publié: (2025)

Pharmacokinetics of Nitazoxanide Dry Suspensions After Single Oral Doses in Healthy Subjects: Food Effects Evaluation and Bioequivalence Study
par: Chenning Zhang, et autres
Publié: (2024)

Pharmacokinetics of Depemokimab Delivered by Safety Syringe Device or Autoinjector in Healthy Adults: A Phase 1, Single‐Dose Study
par: Stein Schalkwijk, et autres
Publié: (2025)

Phase 1 Studies to Assess Inhaled Seralutinib as a Perpetrator or a Victim of Drug‐Drug Interactions in Healthy Participants
par: Jianke Li, et autres
Publié: (2024)

Pharmacokinetics, Safety, and Tolerability of Cedirogant in Healthy Japanese and Chinese Adults
par: Mohamed‐Eslam F Mohamed, et autres
Publié: (2024)

Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Pritelivir and Its Metabolites
par: Katharina Erb‐Zohar, et autres
Publié: (2024)

Bioequivalence and Pharmacokinetic Evaluation of Regorafenib Tablets in Healthy Chinese Volunteers
par: Zhaoyu Wang, et autres
Publié: (2024)

Comparison of the Pharmacokinetics of Three Budesonide Formulations in Healthy Chinese Subjects
par: Tengrui Yin, et autres
Publié: (2025)

Intravenous Ganaxolone: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability in Healthy Adults
par: Maciej Gasior, et autres
Publié: (2024)